Allergan Investors Lose Class Cert. Bid Over 'Serial Litigant'
By Mike LaSusa (September 29, 2020, 11:39 PM EDT) -- Allergan investors lost a bid to pursue a stock-drop suit as a class action against the pharmaceutical company, with a New York federal judge ruling Tuesday that the proposed lead plaintiff, which Allergan derided as a "serial litigant," isn't fit to represent the proposed class.
U.S. District Judge Colleen McMahon said the lead plaintiff, the Boston Retirement System, hadn't obeyed her instructions with respect to the structure of its legal team.
"There is absolutely no question that this action should proceed as a class action. It is a garden-variety securities fraud suit, a type of action particularly well suited to class...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!